Results 51 to 60 of about 14,491 (226)

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report

Current Problems in Cancer: Case Reports, 2022
Background: Anaplastic Lymphoma Kinase (ALK) inhibitors are tyrosine kinase inhibitors used as molecular-targeted therapy for non-small cell lung cancers (NSCLC) harbouring ALK translocations.
Robina Aerts, Jan Brijs, Tine Van Nieuwenhuyse, Mariëlle Beckers, Christophe Dooms, Els Wauters, Kristiaan Nackaerts   +6 more
doaj   +1 more source

Incidence and risk factors of pneumonitis in ALK-rearranged non-small cell lung cancer patients treated with alectinib and thoracic radiotherapy. [PDF]

Transl Lung Cancer Res
Background Alectinib and thoracic radiotherapy (TRT) are important modalities in the management of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), both of which can cause treatment-related pneumonitis (TRP), a serious ...
Xu Y, Qie W, Zhong X, Li B, Yang L, Zou B, Wang L, Yu J.   +7 more
europepmc   +2 more sources

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. [PDF]

, 2016
Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).
Ambrogio, Chiara, Bombelli, Silvia, Casati, Cesare, Ceccon, Monica, Chiarle, Roberto, Compagno, Mara, Di Giacomo, Filomena, Gambacorti-Passerini, Carlo, Giudici, Giovanni, Manazza, Andrea D, Mastini, Cristina, Menotti, Matteo, Merlo, Maria Elena Boggio, Mologni, Luca, Poggio, Teresa, Rigolio, Roberta, Turner, Suzanne D, Varesio, Lydia M, Voena, Claudia   +18 more
core   +1 more source

Successful treatment with crizotinib after alectinib-induced interstitial lung disease

SAGE Open Medical Case Reports, 2021
Although alectinib is a well-tolerated and highly effective inhibitor of a second-generation anaplastic lymphoma kinase, special attention should be paid to the possibility of potentially severe and fatal adverse events such as interstitial pneumonia. We
Ning Zhu, Shanhong Lin, Lei He, Linfeng Wang, Weiliang Kong, Chao Cao   +5 more
doaj   +1 more source

Differential protein stability and clinical responses of EML4 - ALKfusion variants to various ALK inhibitors in advanced ALK - rearranged non-small cell lung cancer [PDF]

, 2017
BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely.
Bayliss, Camidge, Choi, Choi, Eichenmuller, Eisenhauer, Heuckmann, Kwak, Lei, Li, Lin, Matikas, Oken, Palacios, Richards, Richards, Rikova, Sasaki, Seto, Shaw, Shaw, Smith, Soda, Soda, Solomon, Yoshida   +25 more
core   +1 more source

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer [PDF]

, 2023
Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3-mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma kinase (ALK).
Ando, Chihiro, Fujii, Masanori, Hara, Naofumi, Hotta, Katsuyuki, Ichihara, Eiki, Kano, Hirohisa, Kiura, Katsuyuki, Kondo, Takumi, Kubo, Toshio, Maeda, Yoshinobu, Makimoto, Go, Matsuoka, Ken-Ichi, Morita, Ayako, Nakasuka, Takamasa, Ninomiya, Kiichiro, Nishi, Tatsuya, Nishii, Kazuya, Ohashi, Kadoaki, Tabata, Masahiro, Takada, Kenji, Watanabe, Hiromi   +20 more
core   +1 more source

EML4-ALK variants: biological and molecular properties, and the implications for patients [PDF]

, 2017
Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung
Bayliss, R, Jackson, G, Sabir, SR, Yeoh, S   +3 more
core   +1 more source

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. [PDF]

, 2023
INTRODUCTION: This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.
Ahn, M-J, Burotto, M, He, J, Kim, D-W, Lin, HM, Liu, G, Liu, X, Lu, S, Ma, X, Popat, S, Vincent, S, Yang, JC-H, Yin, J, Zhao, Y   +13 more
core   +1 more source

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

JTO Clinical and Research Reports, 2022
Introduction: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment.
Johannes Noé, PhD, Walter Bordogna, PhD, Venice Archer, MD, Vlatka Smoljanovic, MD, Magalie Hilton, MSc, Ryan Woodhouse, BSc, Simonetta Mocci, MD, PhD, Shirish M. Gadgeel, MD   +7 more
doaj   +1 more source